This report was prepared by Elsevier’s Analytical Services in collaboration with Hong Kong Baptist University, which funded the report and provided expertise and guidance throughout the creation process.

About Elsevier

Analytical Services is part of Elsevier’s Research Intelligence portfolio of products and services, which serve research institutions, government agencies and funders. Whether your institution is conducting research or funding it, Research Intelligence provides the objective and analytical insight needed to improve your ability to establish, execute and evaluate national and institutional research strategy.

For more information about Elsevier’s Research Intelligence portfolio, please visit: www.elsevier.com/research-intelligence

Elsevier, a global leader in information and analytics, helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. Growing from our roots in publishing, we have supported the work of our research and health partners for more than 140 years. Elsevier offers knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support and health education. Elsevier publishes over 2,650 digitised journals, including The Lancet and Cell; our 42,000 eBook titles; and our iconic reference works, such as Gray’s Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

See www.elsevier.com

About Hong Kong Baptist University

Hong Kong Baptist University (HKBU) focuses its research efforts through four strategic clusters: Creative Media and Practice, Health and Drug Discovery, Data Analytics and Artificial Intelligence, and Humanities and Culture. These clusters foster collaboration, encouraging faculty to engage in innovative and impactful interdisciplinary research.

The School of Chinese Medicine (SCM) is a key contributor to the Health and Drug Discovery cluster committed to both inheritance and innovation in Chinese Medicine, leading initiatives in precision medicine and phenomics, translational medicine, and innovative drug discovery. Supported by 15 specialized research centers, SCM excels in the authentication and testing of Chinese Medicines in cancer and inflammation, bone and joint diseases, pain, Parkinson’s Disease, nephrology, intestinal immunology, bioinformatics and translational science, phenome research, system medicine, regenerative medicine, drug discovery, clinical trial, and standardization of Chinese Medicines. Notable achievements include developing the first designated orphan drug and a new botanical drug in Hong Kong authorized by the FDA for clinical trials, patents and publications in reputable medical journals including Nature Medicine, Signal Transduction and Targeted Therapy, Annals of Internal Medicine, and more.

Founded in 1956, HKBU is a leading higher-education institution with seven faculties and schools, home to around 5,000 postgraduates and more than 7,000 undergraduates. It established Hong Kong’s first government-funded undergraduate programs in Chinese Medicine and pharmacy. HKBU ranked 2nd globally in quality education in the Times Higher Education Impact Rankings 2024. With 16 Chinese Medicine clinics and as the first operator of The Chinese Medicine Hospital of Hong Kong, HKBU supports comprehensive medical teaching, service, and research.